GlassScriptPhysician profile
Anant Agarwalla
NPI 1326458589
$6,859.06
in general payments reported to CMS, 2019-2025
30 companies · $2,008 in 2025
The $2,008 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.53 · 2020: $206 · 2021: $139 · 2022: $994 · 2023: $1,884 · 2024: $1,611 · 2025: $2,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,360 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,360.43 |
| Education | $142.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,327.16 | 2019-2025 | Linzess, Rinvoq, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $735.06 | 2020-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $708.80 | 2022-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $617.09 | 2020-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $515.87 | 2020-2025 | |
| Genzyme Corporation | $343.62 | 2021-2025 | |
| Ardelyx, INC. | $271.80 | 2023-2025 | Ibsrela |
| Celgene Corporation | $254.28 | 2022-2024 | Zeposia |
| Lilly USA, LLC | $244.14 | 2023-2025 | Omvoh, Mounjaro, Zepbound |
| Stryker Corporation | $211.67 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $167.76 | 2023-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $160.05 | 2022-2025 | Ocaliva |
| Ethicon US, LLC | $140.34 | 2022 | |
| Ferring Pharmaceuticals INC. | $133.98 | 2023-2024 | Rebyota |
| Madrigal Pharmaceuticals | $132.47 | 2025 | Rezdiffra |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $111.06 | 2022 | |
| Qol Medical, LLC | $108.98 | 2023-2025 | Sucraid |
| Novo Nordisk INC | $96.43 | 2023 | |
| Nestle Healthcare Nutrition INC. | $95.11 | 2022-2023 | |
| Pfizer INC. | $90.08 | 2024-2025 | |
| Digestive Care, INC. | $70.73 | 2024 | Pertzye |
| Celltrion USA INC. | $61.64 | 2024-2025 | Zymfentra, Vegzelma |
| Regeneron Healthcare Solutions, INC. | $48.04 | 2022-2024 | Dupixent |
| Aimmune Therapeutics, INC. | $47.91 | 2025 | Zenpep |
| Braintree Laboratories, INC. | $42.61 | 2023-2024 | Sutab, Suflave |
| Vivus LLC | $27.74 | 2025 | Qsymia |
| Exact Sciences Corporation | $25.35 | 2024 | Cologuard Collection Kit |
| Amgen INC. | $25.30 | 2025 | Uplizna |
| Evoke Pharma, INC. | $22.23 | 2023 | Gimoti |
| Ironwood Pharmaceuticals, INC | $21.76 | 2023 | Linzess |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anant Agarwalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.